Last mentioned: Mar 7, 2026
First Approvals
Anticipated first wave of gene therapy approvals under the new streamlined framework.
Supply Chain Assessment
Logistics managers begin evaluating damage to facilities and transit route viability.
Casualties Confirmed
Authorities confirm a total of six deaths and transition to search and recovery operations.
Michigan Impact
Severe cells move into Michigan, causing significant structural damage and initial fatality reports.
Oklahoma Touchdowns
First suspected tornado touchdowns reported in Oklahoma; emergency sirens activated.
Storm Watches Issued
National Weather Service issues severe storm watches for parts of the Midwest and Plains.
Storm Development
Severe weather systems intensify across the Midwest and Central Plains.
Tornado Touchdowns
Suspected tornadoes strike communities in Oklahoma and Michigan within hours of each other.
Emergency Response
Authorities confirm six deaths and launch large-scale search and rescue operations.
Framework Formalized
FDA officially announces the 'plausible mechanism' framework for ultra-rare disease therapies.
Draft Guidance Issued
FDA releases draft guidance on using surrogate endpoints for gene therapy accelerated approval.
START Pilot Launch
FDA launches the Support for clinical Trials Advancing Rare disease Therapeutics (START) pilot program.
A series of suspected tornadoes struck Michigan and Oklahoma on March 7, 2026, resulting in at least six confirmed fatalities. Emergency responders are currently conducting search-and-recovery operations amidst widespread debris as authorities assess the full extent of the damage.
A series of suspected tornadoes across Michigan and Oklahoma has resulted in at least six fatalities and widespread structural damage. These events threaten critical automotive manufacturing corridors and central U.S. freight transit routes, forcing immediate logistics reassessments.
The FDA has officially introduced a streamlined regulatory pathway for gene therapies, allowing for accelerated approval based on 'plausible mechanisms' and biomarkers rather than traditional clinical outcomes. This landmark shift aims to fast-track treatments for ultra-rare diseases where traditional large-scale clinical trials are statistically impossible.